about
The neoepitope landscape in pediatric cancers.Breast Cancer Immunotherapy: Facts and Hopes.Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy.Increasing the safety and efficacy of chimeric antigen receptor T cell therapy.Treatment strategies for DNA repair-deficient prostate cancer.Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer.Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines.Bioengineering of Artificial Antigen Presenting Cells and Lymphoid Organs.Activation of IRF3 contributes to IFN-γ and ISG54 expression during the immune responses to B16F10 tumor growth.Enhanced Susceptibility of Ogg1 Mutant Mice to Multiorgan Carcinogenesis.APP mouse models for Alzheimer's disease preclinical studies.The Potential and Challenges of Exploiting the Vast But Dynamic Neoepitope Landscape for Immunotherapy.Novel insights into the HLA class I immunopeptidome and T-cell immunosurveillance.Resources for Interpreting Variants in Precision Genomic Oncology Applications.'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization.Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients.Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma.Hitting the Target: How T Cells Detect and Eliminate Tumors.Informatics for cancer immunotherapy.Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy.Trial watch: Immune checkpoint blockers for cancer therapy.Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies.Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer.Towards personalized, tumour-specific, therapeutic vaccines for cancer.Can radiotherapy potentiate the effectiveness of immune checkpoint inhibitors in lung cancer?Advances in immunotherapy for pediatric acute myeloid leukemia.Targeting tumor microenvironment to curb chemoresistance via novel drug delivery strategies.Treating hematological malignancies with cell therapy: where are we now?The dawn of vaccines for cancer prevention.Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors.Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment.High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferonγ-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome.Uncovering cancer: How enlisting T cells can boost the power of immunotherapy.Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies.Photochemical Internalization of Peptide Antigens Provides a Novel Strategy to Realize Therapeutic Cancer Vaccination.Programmed self-assembly of peptide-major histocompatibility complex for antigen-specific immune modulation.Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy.Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma.Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance.Targeting Immune System Alterations in Hodgkin Lymphoma.
P2860
Q38601828-8345C5A5-6379-4B43-BA78-0BC41101D5DCQ38628198-659663BB-4AA4-4212-B5C4-20CDCB95B1C9Q38645338-4B65BFEF-38A2-4A04-8150-FE28CCBE9765Q39256918-536D7D3D-858C-45D7-B7C8-BF48FE041CBBQ39345771-9136F570-9C45-4109-8D9F-57D909BB4B35Q39438805-2EDDB0F8-94FD-4EC0-AA75-F94D24375A1CQ39450802-B6F763DB-16F3-4B0B-A202-A7B6D659F17CQ40044791-A088413F-70B5-44F2-86E2-3D28E6671934Q40145249-A6E51E75-BCAE-43EB-B123-BC736769FF2AQ41574483-201219BC-FC57-46F5-BC74-9911F4872556Q41582196-71425AD0-EA07-4F9F-A972-C7DD02255A0DQ41673084-2EE781D3-D7BB-48CC-9209-A438A9DFA617Q42346977-45F61674-5E89-4269-9E53-727D3980D9CDQ42363061-418698C6-E831-4590-9B46-FFFCD37F97E8Q45718710-B96A43A0-991C-499B-980C-D0B100359CE3Q46030309-D4703204-8876-4C57-9E79-D0B5FAD1FC52Q47134263-A571AD9E-B291-4AFA-82CE-606458C7A6D2Q47222791-50AF4C16-B086-4024-BBA2-359CC54699A8Q47290509-7292343A-71C7-460D-B451-6DC15710E01FQ47320909-7496FC69-86EE-40C0-A4F3-2FE334E708CFQ47393365-934B9507-B2AA-4767-81A7-8E006D4229A1Q47557087-760244E1-5C8A-4C34-974F-C8A28B9A2A33Q47701712-DD33E99B-5186-4E3A-A39B-A9185B10BED3Q47789519-3A5D7EB2-A549-4D73-A2A7-4FFFEF86581CQ47821832-FC6C8BF9-6E88-44ED-B177-306D3310138EQ47930962-6135C5B3-324F-4DAE-B563-6534137AD954Q48308048-A52AD168-B8E3-4A8F-B08A-E8C28C9D9B57Q48640926-D076EE2E-B05F-4335-A620-33769FCD0819Q49566629-AA246EB3-B6AF-4AAB-A6BF-30C21BE4B88EQ49593797-27E7FE8F-AA5A-40C6-B52D-F11152795671Q49835172-D0772DD3-D005-413A-AEE6-3F5C5139ADA5Q49836890-EDD3C363-7599-43B6-8890-70791C4DD126Q50197357-DB94E548-D80F-4890-8DEA-9CC193ED8BE1Q51804722-3EC90336-B620-447B-8D3C-A923648EEF66Q52316326-1A1E9AFA-5717-4ED3-812D-D90FF31BEEA0Q52327552-2BF4EF9B-F9BD-4123-BD20-52C62098064AQ52606149-2665877A-7EA1-44C8-B064-EB35BC313ABEQ52606456-8872B070-17AF-41B8-9253-F6919C75B77BQ52723482-BEA3F8E3-3EFF-4A6C-8478-8B7B260602CBQ53123844-2D9F2AFF-A249-4CC7-A771-DF44C3650AF6
P2860
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Targeting neoantigens to augment antitumour immunity.
@en
Targeting neoantigens to augment antitumour immunity.
@nl
type
label
Targeting neoantigens to augment antitumour immunity.
@en
Targeting neoantigens to augment antitumour immunity.
@nl
prefLabel
Targeting neoantigens to augment antitumour immunity.
@en
Targeting neoantigens to augment antitumour immunity.
@nl
P2093
P2860
P356
P1476
Targeting neoantigens to augment antitumour immunity.
@en
P2093
Burles A Johnson
Daniel A Laheru
Eric R Lutz
Mark Yarchoan
P2860
P2888
P304
P356
10.1038/NRC.2016.154
P407
P577
2017-02-24T00:00:00Z